The Remarkable Beneficial Effect of Adding Oral Simvastatin to Topical Betamethasone for Treatment of Psoriasis: A Double-blind, Randomized, Placebo-controlled Study

Naseri, Mitra; Hadipour, A; Sepaskhah, Mozhdeh; Namazi, Mohammad-Hassan

doi:10.4314/njm.v19i1.54216

Cited by 35 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[26] In another study Naseri et al ., evaluated the efficacy of oral simvastatin on improvement of psoriasis. [17] This paper has shown significantly more reduction of Psoriasis Area Severity Index score in the group received oral simvastatin compared to group who did not ( P = 0.001).…”

Section: Discussionmentioning

confidence: 84%

See 1 more Smart Citation

A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients

et al. 2017

View full text Add to dashboard Cite

Background:Vitiligo, a common disorder of depigmentation, is often difficult to treat. Corticosteroids are known to be effective, but with modest results. Although simvastatin has been reported to be effective for immunorelated dermatologic disorders including vitiligo, controlled trials are lacking. This study was conducted to compare the efficacy of topical betamethasone valerate 0.1% cream (as a standard method of treatment for vitiligo) versus a combination of betamethasone valerate plus oral simvastatin in the treatment of vitiligo.Materials and Methods:Eighty-eight subjects with symmetric vitiligo who had body surface involvement up to 20% were divided randomly into two groups. Group A were treated with betamethasone valerate 01% cream twice daily and Group B with betamethasone valerate 01% cream twice daily and oral simvastatin 80 mg daily for 12 weeks. Finally, 46 patients completed treatment after 12 weeks in both groups. The results were evaluated by a blind dermatologist using Vitiligo Area Scoring Index (VASI) score at baseline, 4th, 8th, and 12th week of treatment. In a similar way, subjective assessment performed by patients based on photo evaluation at the end of the study.Results:Despite a continuous reduction in VASI score in both groups, according to both physician (P = 0.13) and patient (P = 0.374) assessment oral simvastatin was not statistically more effective than conventional treatment of vitiligo.Conclusion:This study indicates that oral simvastatin is not associated with significant impacts in the treatment of vitiligo as compared to other inflammatory dermatologic conditions such as psoriasis. Indeed, other studies should be initiated regarding exact molecular and cellular effects of statins in the treatment of vitiligo.

show abstract

Section: Discussionmentioning

confidence: 84%

“…[1516] Recently, a randomized control trial showed a remarkable benefit of adding oral simvastatin in the treatment of psoriasis. [17]…”

Section: Introductionmentioning

confidence: 99%

A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, emerging data have suggested that the pleiotropic eVects of statins may extend to a larger number of disorders, as evidenced by (1) improved quality of life, decreased inXammation and enhanced response to topical steroid therapy in patients with psoriaris and psoriatic arthritis [75,76]; (2) decreased postinXammatory vascular remodeling and endothelial dysfunction in children and young adults with Kawasaki disease [77,78]; (3) improved disease activity in patients with active ankylosing spondylitis [79]; (4) improved endothelial function and decreased proteinuria in Behcet's disease patients [80,81]; and (5) a case of To determine the eVects of Xuvastatin on prothrombotic and pro-inXammatory markers therapy-refractory juvenile idiopathic arthritis treated with oral atorvastatin [82]. It is important to note that although rare, adverse reactions of statins have included the triggering of de novo autoimmune disorders, in particular inXammatory myopathies.…”

Section: Discussionmentioning

confidence: 99%

The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review

2011

View full text Add to dashboard Cite

The hydroxy-methyl-glutaryl-CoA reductase inhibitors (statins) are used extensively in the treatment for hyperlipidemia. They have also demonstrated a benefit in a variety of other disease processes, including a wide range of rheumatologic disorders. These secondary actions are known as pleiotropic effects. Our paper serves as a focused and updated discussion on the pleiotropic effects of statins in rheumatologic disorders and emphasizes the importance of randomized, placebo-controlled trials to further elucidate this interesting phenomenon.

show abstract

“…[28] This paper has shown significantly more reduction of PASI score in the group received oral simvastatin compared to group who did not ( P = 0.001). [18]…”

Section: Discussionmentioning

confidence: 99%

“…[89] With clarification of the immunomodulatory aspect of statins besides antihyperlipidemic effects,[101112131415] several studies on the potential aspect of oral simvastatin in the treatment of psoriasis have been carried out. [161718]…”

Section: Introductionmentioning

confidence: 99%

Efficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasis

et al. 2014

View full text Add to dashboard Cite

Background:Psoriasis is a common dermatologic disorder, with fluctuating response to treatment. Considering the proven immunomodulatory effects of oral simvastatin in psoriasis, this trial study was enrolled to determine whether the topical form has also antipsoriatic effects. Vitamin D analogs known to be effective and are considered the first line of therapy in mild to moderate cases. In this study, the efficacy of topical calcipotriol 0.005% ointment (as a standard method of treatment for psoriasis) versus combination of calcipotriol plus topical simvastatin is compared in the treatment of psoriasis.Materials and Methods:A total of 80 subjects with symmetric psoriasis who had body surface involvement up to 20% were divided randomly into 2 groups. Group A were treated with calcipotriol 0.005% ointment twice daily and Group B with calcipotriol 0.005% ointment twice daily and simvastatin 3% ointment twice daily for 12 weeks. The results were evaluated by a Blind Dermatologist using psoriasis area severity index (PASI) score at baseline, 4th, 8th and 12th week of treatment. In a similar way, a subjective assessment performed by patients based on photo-evaluation at the end of the study.Results:Despite a continuous reduction in PASI score in both groups, according to both physician (P = 0.603) and patient (P = 0.243) assessment topical simvastatin was not statistically more effective than conventional treatment of psoriasis at the end of the study.Conclusion:This study indicates that topical simvastatin is not associated with significant impacts in the treatment of psoriasis as compared to oral form. This study indicates that psoriasis is a systemic disorder with variable skin manifestations.

show abstract

The Remarkable Beneficial Effect of Adding Oral Simvastatin to Topical Betamethasone for Treatment of Psoriasis: A Double-blind, Randomized, Placebo-controlled Study

Cited by 35 publications

References 0 publications

A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients

A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients

The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review

Efficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasis

Contact Info

Product

Resources

About